BioGaia expands network in the oral health field BioGaia

BioGaia has signed four different distribution agreements for the exclusive rights to sell its oral health products. Agreements have been made with Streuli Pharma AG for Switzerland, Plac Control for Greece, PharmaPal Drugstore LLC for United Arab Emirates and George Petrou Ltd for Cyprus. Further, Sunstar has relaunched the products in Germany. In all countries the products will be sold under the BioGaia brand and launches are planned to take place during 2013 and 2014. In September 2013 Sunstar, one of the world’s leading companies in oral care, relaunched BioGaia’s oral health products in Germany. ”We are pleased to announce distribution agreements for a further five countries where BioGaia’s oral health products soon will be available for a large number of consumers. With the rapidly increasing body of clinical proof for Lactobacillus reuteri Prodentis and the strong interest in the products among international distribution partners, we are confident that the oral health area will become an important part of our business”, says Peter Rothschild, President BioGaia. BioGaia’s oral health products contain the patented and well-studied probiotic Lactobacillus reuteri Prodentis (http://www.biogaia.com/clinical -studies?field_bg_indication_tid=194&age=All&author=All). The portfolio consists of lozenges (http://www.biogaia.com/product/biogaia-prodentis-oral-lozenges) and chewing gum (http://www.biogaia.com/future-launches) for consumers and oil drops for professional use. Today BioGaia's oral health products are sold in more than 20 countries worldwide. Latest press releases from BioGaia 2013-10-23 BioGaia AB Interim report 1 January-30 September 2013 2013-10-10 Lactobacillus reuteri Protectis only probiotic effective in treating colic 2013-08-22 BioGaia AB Interim report 1 January-30 June 2013 BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 29 October 2013, 10:30 am CET. For additional information please contact Peter Rothschild, Chief Executive Officer, BioGaia: 46 8 555 293 00 BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health -enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com